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Childhood immunisation is one of the greatest public health successes of the last century. Vaccines contain an
active component (the antigen) which induces the immune response. They may also contain additional
components such as preservatives, additives, adjuvants and traces of other substances. This review provides
information about risks of hypersensitivity reactions to components of vaccines. Furthermore, recommendations to
avoid or reduce reactions to vaccine components have been detailed.
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Vaccines contain an active component (the antigen) and
additional components. Allergy to additional components,
especially foods, is not uncommon in childhood. Egg
allergy affects 2.5% of infants [1], cow’s milk allergy 2.2%
[2,3]. Despite a long-lasting debate, the approach to
vaccination in children allergic to additional constituents
remains one of ambiguity and concern for most pediatric
health care professionals. The Committee of the Italian
Pediatric Society ofAllergology and Immunology selected
for their expertise in research and clinical practice of
management of vaccination in at risk children, convened
in April 2013 to establish the structure of this document.
Three panelists were delegated to draft a document
addressing the identified key questions on commercially
available vaccines. The document was based on agreement
between panelists and on a comprehensive overview of
the literature. A careful evaluation of the literature was
performed. PubMed database was queried for articles
published in the last 10 years describing allergic reactions
following vaccination. The literature search was under-
taken in May 2014. The following search terms were
included: vaccine, adverse effect, adverse event, allergy,
hypersensitivity, cow’s milk, egg, yeast, gelatin, dextran,* Correspondence: carlo.caffarelli@unipr.it
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reproduction in any medium, provided the origthimerosal, antibiotic, adjuvant, stabilizer, latex, aluminium,
phenoxyethanol. The search was limited to articles in
English, humans and age 0–18 years. Articles were consi-
dered if they described systematic reviews, meta-analysis,
randomized-controlled trials, observational studies, and
case reports. The search found 1937 references. Articles,
including those on ancient vaccines, that were useful for
the purpose of this article were cited. Relevant articles
published before 2004 were either familiar to the authors
or they were selected by searching the reference lists
of identified articles. The expert panel convened in
June 2014 to review distinct aspects of the document
and to reach consensus for the final document.Review
Clinical approach
The vaccinator must carefully evaluate, prior to vaccine
injection, if any risk of developing hypersensitivity or aller-
gic reactions exists to prevent potentially severe hypersensi-
tivity reactions. Therefore parents must be asked whether
the child has ever experienced any allergic sign or symptom
after a vaccination even if they were not reported or diag-
nosed to be an allergy. Vaccinator should be trained to
recognize when the referred reactions were allergic. Fur-
thermore, in the pre-vaccine anamnesis, all prior adverse
reactions must be addressed, including those to additional
vaccine components such as: culture media antigens, adju-
vants, preservatives, stabilizers, antimicrobial agents, addi-
tives [4,5]. When an adverse reaction to a vaccine or to itsis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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investigated: route of administration (oral or parenteral),
clinical signs and symptoms, time and severity of reactions,
treatment and therapies provided. Severe asthma and
anaphylaxis must be ruled out: these conditions always
require an hospital supervised vaccination [6]. In a suspect
of allergic reaction to vaccine or its components arises,
patients need to be referred for an allergy consultation
before vaccination.
Potential allergens
Any vaccine contains culture media antigens, which are
protein-based, and could be responsible for hypersensitivity
reactions (Table 1).
Egg
Egg allergy is one of the most frequent food allergy
in infants. Although egg tolerance could spontaneouslyTable 1 Reactions to vaccine components in studies with mor
Vaccine component Studies
Egg Measles-mumps-rubella
Goodyear-Smith et al. 2005 [9]
Erlewyn-LajeunesseM et al. 2008 [10]
Govindaraj P et al. 2009 [11]
Cronin J et al. 2012 [12]
Andersen DV et al. 2013 [13]
Total
Influenza
Cerecedo C et al. 2007 [27]
Esposito S et al. 2008 [28]
Chung E et al. 2010 [29]
Gagnon R et al. 2010 [24]
Greenhawt MJ et al. 2010 [30]
Pien GC et al. 2010 [31]
Webb et al. 2011 [32]
Erlewyn-Lajeunesse M et al. 2011 [21
Howe et al. 2011 [25]
Owens et al. 2011 [33]
Shuler JE et al. 2011 [34]
Fung et al. 2012 [35]
Greenhawt MJ et al. 2012 [26]
Wainwaring Upton JE et al. 2012 [36]
Des Roches et al. 2012 [23]
Forsdhal BA et al. 2012 [37]
Total
Yeasts DiMiceli L et al. 2006 [45]
Dextran Zanoni G et al. 2008 [62]
Thimerosal Wattanakrai P et al. 2007 [72]develop, about 60% of chidren with egg allergy do not
tolerate egg at 6 years of age [7]. Egg proteins, especially
ovoalbumin, could be present in several vaccines prepared
on embryonated chicken eggs. Egg proteins concentrations
are not usually reported and could vary among vaccine’s
brands, batches and cultivation’s protocols. Concentrations
are usually higher on embryonated chicken eggs vaccines
(influenza, yellow fever, rabies) and are lower on chicken
embryos or fibroblasts of chicken embryos vaccines
(Measles-Mumps-Rubella, tick-borne encephalitis). The
European Union legislation has established 2 μg/ml as the
maximum egg proteins concentration allowed, which has
been demonstrated to be a safe amount in patients with
previous egg’s anaphylaxis. Therefore, no significant risk
of allergic reactions following vaccination should be
foresighted in patients with egg’s allergy [8], even
though all scientific studies referred to oral rather
than parenteral contact [8].e than 25 participants
Partecipants, N Allergic reactions N (%)
73 0 (0%)
100.000 42 (0.04%)
45 0 (0%)
310 6 (1.9%)
32 0 (0%)
100.460 48 (0.04%)
26 0 (0%)
44 3 (6.8%)
171 29 (16.9%)
830 9 (1.08%)
105 0 (0%)
62 0 (0%)
152 2 (1.3%)
] 3640 88(2.41%)
135 0 (0%)
64 4 (6.25%)
62 4 (6.4%)
56 2 (3.5%)
105 0 (0%)
77 0 (0%)
367 13 (3.54%)
80 3 (3.75%)
5982 157 (2.62%)
107 15 (14%)
100.000 19 (0.01%)
46 0 (0%)
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vaccine is grown on cell cultures employing chicken
embryo-fibroblasts. This vaccine contains minimal
amounts of egg proteins, from nanograms to
picograms, often not precisely reported. Therefore, this
vaccine shows a very low risk of allergic reactions, even
in egg’s anaphylaxis [9-13] (Table 1). In Europe,
prevalence of anaphylaxis due to MMR vaccine is
estimated at 1.2 cases per million doses [14]. In the US,
an incidence of 3.5 cases per 1,000,000 doses has been
reported [15]. Interestingly, the vast majority of allergic
reactions to MMR is observed in patients without egg
allergy [16]; hence, it is probable that the real triggers
are other vaccine’s components, such as gelatin [17].
Available data show no additional risk for immediate
reactions in egg-allergic children, compared to non
allergic, with commercial MMR or measles vaccines.
In the Italian National Health Instiute website it is
clearly reported that all children with egg-allergy must
be vaccinated and no specific precautions are needed,
not even in previous egg anaphylaxis [18]. However, a
review [16] that analyzed all severe allergic reactions to
MMR referred from 1966 to 1999, reported 14 local
reactions and 16 systemic reactions in 1803 egg-allergic
children undergone to MMR vaccine. None of these
reactions was fatal. In 3 out of 16 systemic reactions a
proper anamnesis was collected and it was positive for
a previous severe allergic reaction after egg ingestion
and/or a chronic asthma. Therefore, it has been
suggested, in case of severe previous egg anaphylaxis or
moderate reactions in chronic active asthma, to
administer the vaccine under hospital supervision.
Sensitivity and specificity of skin prick test with MMR
vaccine are low and not predictive of serious reactions,
thus are not recommended [19,20].
Influenza vaccine - Despite a theoretical risk of
hypersensitivity reactions to minimal amount of
egg-proteins [21,22] in influenza vaccine, studies,
including papers and abstracts, from 1977 to 2012
showed that in 4172 egg-allergic patients (and 513
with severe allergic reaction), safety of influenza vaccine
has been proven, with especial regard to both severe
anaphylactic reactions (respiratory distress or
hypotension) and mild reactions (urticaria or mild
wheezing) [23]. These allergic reactions rates did not
differ significantly from those in non-egg-allergic
controls [24-26]. In investigations published in the last
ten years [21,23-37] the frequency of allergic reactions
to vaccine was 2.62% in 6532 subjects (Table 1). The
American Academy of Paediatrics [19] has recently
stated that the risks of missing influenza vaccination
outweigh those from vaccination itself. Therefore, egg
allergy of any severity (including anaphylaxis) is not a
contraindication to the administration of influenzavaccine. However, influenza vaccine should be
administrated when resuscitation facilities are available,
and the patient should be observed in the office for
30 minutes after immunization [19]. In egg-allergic
patients the injectable vaccine should be preferred
rather than intranasal preparation because of an higher
amounts of ovalbumin in the latter [5]. Influenza
vaccine contains less than 1 μg/dose of ovalbumin.
Those with an higher amount (more than 1.2 μg/mL)
should be avoided in egg-allergic subjects [38].
Influenza vaccine cultured on human cells or insect
culture are not approved for pediatric use.
Administration of influenza and MMR vaccines -
All egg-allergic children can receive influenza or
MMR vaccine in primary care physician’s office. Or in
vaccination centre provided with appropriate
equipment and medications and with a 60 minutes
post-vaccine observation (Table 2). It is recommended
to investigate all suspected egg allergy before
vaccination. Due to low sensitivity and specificity, skin
prick test with influenza vaccine is not recommended.
As well, divided doses of vaccine is not required
because even in most severe egg-allergy vaccine can
be tolerated in full dose. Children with a previous
history of severe reactions to egg (anaphylaxis) should
instead receive their vaccine in a hospital supervision
[16]. This recommendation, however, shows a low
grade of strength and should be reviewed in the future
guidelines [39].
Yellow fever vaccine - Yellow fever is an acute viral
disease caused by Flavivirus and transmitted by the bite
of mosquito (Aedes Aegypti). It is endemic in South
America and Africa and has an high mortality. Yellow
fever vaccination is, therefore, required for traveling in
endemic countries. Yellow fever vaccine is grown in
chicken embryos and contains higher amounts of
egg-proteins in comparison with MMR and influenza
vaccines. Unlike influenza and MMR vaccines, all
subjects with egg-allergy and previous systemic
reactions should receive yellow fever vaccine under
hospital supervision. Patients with egg allergy should be
evaluated before vaccination, with skin prick test and
serum specific IgE to eggs [39]. When there is an
history of anaphylaxis to egg, it may be performed a
skin prick test with a 1/10 dilution of vaccine, and, if
negative, with undiluted vaccine. If skin prick tests are
negative, an intradermal test should be performed with
a 1/100 dilution (1/10 dilution has been demonstrated
to be irritative) [39]. If all skin tests are nega-tive,
vaccine could be normally administered, with a
60 minutes post-vaccine observation (Table 2). If
skin tests are positive, vaccine should be injected in
graded dose under hospital supervision. It has been
demonstrated that an intradermal 1/5 dose of vaccine
Table 2 Vaccination protocols in allergic subjects
Allergen Vaccine Vaccination protocol Setting
Egg Yellow fever* Rabies* ° Influenza
MMR Tick-borne en- cephalitis
MMR and Influenza:
1) If egg-allergy normally administer with a 60 minutes observation 1) Office
2) If egg-anaphylaxis normally administer with a 60 minutes
observation
2) Hospital
Yellow fever:
1) If skin tests are negative: normally administer with a 60 minutes observation Hospital
2) If skin tests are positive: desensitization/graded doses
Cow’s milk OPV, DTP, DT, DTaP, PCV-13 If previous anaphylaxis normally administer with a 60 minutes observation Office
Yeasts Hepatitis B, Quadrivalent HPV,
meningococcal , PCV-13, typhoid (oral)
1) If skin tests with vaccine are negative: normally ad- minister with a
60 minutes observation
Hospital
2) If skin tests with vaccine are positive: desensitiza- tion/graded doses
Neomycin MMR, IPV, rabies, influenza, varicella,
Zoster HepA
1) If local skin reaction: normally administer Office/Hospital
2) If anaphylactic reaction: no vaccine
Gelatin MMR*, Varicella*, Zooster*,
Yellow fever* Rabies °, DTP Influenza
1) If skin tests are negative: normally administered with a 60 minutes
observation
Hospital
2) If skin tests are positive: gelatin-free vaccine or de- sensitization/graded doses
Latex When vaccine has no removable
contaminated part (prefilled syringe),
vaccine should be normally administered
with a 60 minutes observation
Hospital
*High amount. °To be used when polygeline free and egg free vaccine is unavailable.
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who have shown a severe local urticaria reactions [40].
Rabies vaccine - A rabies vaccine without egg and
gelatin is available. Therefore such vaccine should
be administered to subjects with severe allergy to egg
protein or gelatin (Table 2).
Milk
Milk proteins are often used as stabilizers or emulsifiers
in food derivates. Some vaccines (Table 2) could
contains hidden milk proteins, in order to prevent
viruses degradation. Anaphylactic reactions have been
reported in milk and egg-allergic children after MMR
vaccination [41]. Kattan JD et al. [42] have evaluated 8
pediatric patients with previous anaphylaxis arisen within
60 minutes after an acellular diphtheria-tetanus-pertussis
vaccine. In 6 of these children an immediate allergic
reaction to milk proteins have been recorded, and in
5 of these the reaction was a severe one. In all children a
significant sensitization to milk proteins have been
documented within 2 years after vaccine reaction.
Some researchers have observed that culture media
used for commercial vaccine against Chlostridium tetani,
Corynebacterium diphteriae and Bordetella pertussis could
have been supplemented with aminoacids derived
from the hydrolysis of milk proteins. Authors have
demon-strated, with an ELISA essay, a concentration
between 8.1 and 18.3 ng/mL of casein peptides in 8
different batches of DTP (Diphteria-tetanus-pertussis)vaccine [43]. Furthermore, hidden amounts of alpha-
lactalbumin have been detected even in some oral
polio vaccine (OPV) [44]. Four children, receiving
OPV and measles-mumps vaccine at the same time,
have shown severe systemic reactions after vaccines
injections. In these children there was a previous history
of milk proteins allergy but no egg-allergy. As well, skin
prick test and serum specific IgE were positive for milk
proteins but negative for egg proteins. Moreover, skin
prick test with OPV, but not for measles-mumps vaccine,
were positive.Although based on these scattered case-
studies, due to the possible presence of milk proteins in
OPV and DPT vaccine, it has been suggested, in children
with history of milk’s proteins anaphylaxis, a 60 minutes
observation after vaccination (Table 2) [43].
Yeasts
Yeast proteins could be present as Saccharomyces cerevisiae
derived antigens in hepatitis B vaccine (up to 25 mg/dose)
and in quadrivalent human papillomavirus vaccine
(less than 7 mcg/dose) [39]. Yeast is also contained in
pneumococcal 13-valent conjugate (PCV-13), in meningo-
coccal and in oral thyphoid vaccines. Allergic reactions to
yeasts proteins appear to be rare. In the US, in more than
180,000 vaccine adverse reactions, only 15 were resulted
from a reaction to yeast proteins. Furthermore, these
15 cases may have been even related to other vaccine
components [45]. Although rare, in children with proven
yeasts allergy, it is recommended to prefer yeast-free
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not available, these children should be evaluated with
skin prick tests and serum specific IgE dosage to
Saccharomyces cerevisiae before vaccination. If an IgE
sensitization is confirmed, children could receive graded
vaccine; if negative, vaccine could be administered in
the usual manner, with a 60 minutes observation after
injection (Table 2).Additives
Stabilizers
Stabilizers are used to protect vaccine from excessive
heat, drying, antigens’ adherence to vial’s walls. More
common stabilizers are sugars (destran, lactose, saccharose),
aminoacids (glycin, monosodium salt of glutamic acid) and
proteins (gelatin, human serum albumin).Gelatin
Gelatin is a partial hydrolyzed protein derived from animal
connective tissue. It is an ubiquitous antigen: it is
commonly used in foods, juices and wines, confectionery
and it is also used for pharmaceutical purposes in tablets,
caps, suppository, plasma expanders, collagen, stitches.
Gelatin for medical purpose is of bovine or porcine origin
and shows an extensive cross-reactivity (although not with
fish derived gelatin) [46]. It is used as a stabilizer in several
vaccines that are currently available with concentrations
between 15 μg and more than 15,500 μg/dose of vaccine.
[20,47]. The highest concentrations of gelatin are
contained in MMR, rabies, varicella-zoster, oral typhoid
and yellow-fever vaccines, and, in less amounts (up to
2,000 μg/dose) in DTP and influenza vaccines. Gelatin is
the vaccine component responsible for most allergic
reactions to vaccine, for both IgE and non IgE mediated
reactions [48]. Severe reactions due to gelatin have been
described for MMR [47,49], varicella [50-52], yellow fever
[49] and japanese encephalitis vaccines. European and US
studies have documented gelatin specific IgE in 14-28% of
patients with vaccine anaphylaxis, while Japanese studies
reported much higher data (86-100%) in patients with
MMR and varicella vaccines anaphylaxis [47,53]. These
differences could be explained by the different type of
gelatin used in Japan in 1990. In those years, in the US
MMR vaccine contained highly hydrolyzed porcine
gelatin with low molecular weight. In Japan gelatin
was of bovine origin, partially hydrolyzed and with a
small amount of high molecular weight; highly hydrolyzed
porcine gelatin was used from 1998 and was completely
removed from DTP vaccine since 1999. It is possible,
however, that genetic issues should be taken into account.
It has been demonstrated that subjects with HLA-DR9
haplotype carry a 4 times increase risk to develop gelatin
specific IgE [54].However this does not mean that they have clinical
hypersensitivity reactions to gelatin. Nowadays vaccines
contain highly hydrolyzed porcine gelatin, which shows
a lower sensitization rate with a subsequent decrease of
vaccines allergic reactions [55]. For the above mentioned
reasons, every child who needs a gelatin-containing
vaccine should be investigated for previous or possible
gelatin-allergic reactions, especially with food ingestion.
Children sensitized to red-meat (bovine, pork, lamb)
show a higher risk: 16% of children sensitized to bovine
meat and 38% of children sensitized to pork meat
already have specific IgE to gelatin. This sensitization
increases the risk of vaccine allergic reactions [56]. One
study has highlighted that immediate allergic reactions
to bovine meat usually arise in the first year of life and
involve 6% of children affected by atopic dermatitis or
food allergy and 20% of children with milk proteins
allergy [57]. In some subjects even delayed allergic
reactions could be due to red meat (3 to 6 hours
after ingestion). These subjects have a positivity to
serum specific IgE for bovine, pork and lamb meat
and milk, and mild positivity to skin prick test with
commercial extract (wheal less than 4 mm). On the
contrary, they have a strong positivity to skin prick
test with fresh meat [58]. In these patients serum IgE
for galactose-alpha-1,3-galactose are detectable. This
latter compound is a carbohydrate found in mammals
(not in primates or humans) and it is considered, by
some authors, as the major gelatin allergen [56]. All
children with a previous immediate reaction to food
gelatin should undergo an allergy consultation. However,
patients without gelatin allergy may show allergic
reactions to gelatin-containing vaccine [49]. This could be
explained by the different route of exposure to gelatin
allergens. Serum specific IgE are available for gelatin,
while no commercial standardized skin prick extract to
gelatin is available. Skin prick test could be performed
with a prick-by-prick technique dissolving 1 spoon of
sugared gelatin powder in 5 mL of saline solution
(non sugared powder tends to became a gel at room
temperature) [6]. If the skin prick test is negative but
a suggestive history of gelatin-allergy is reported, an
oral provocation test should be suggested [59]. If the
oral provocation test is positive, a skin prick test with
the gelatin-containing vaccine should be performed
and, if negative, the vaccine could be normally given
with a 60 minutes observation. If the skin prick test
is positive, a gelatin-free vaccine should be used or, if
not available, vaccine should be injected in graded
doses (Table 2) [5] in a setting with resuscitation
equipment [60]. For example, for a 0.5 mL vaccine, the
following doses may be given at 15–30 minutes intervals
[20]:0.05 mL 1:10 dilution;0.05 mL full-strength;0.1 mL
full-strength;0.15 mL full-strength;0.2 mL full-strength.
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Dextran has been associated to anaphylaxis following both
Bacillum Calmette Guerin, due to a IgG mediated reaction
with complement fixation [61], and a MMR vaccine that is
no longer available [62]. Delayed localized skin reactions
have been reported, such as maculopapular exanthemas,
urticarial vasculitis and neutrophilic dermatosis [63].
Preservatives
Preservatives are usually added to vaccines preparation
to prevent bacterial or fungal growth or contamination.
Thimerosal - Thimerosal is an organic mercurial
(46% mercury) compound, metabolized to ethyl-mercury
and thiosalicilate. This preservative has been used
by pharmaceutical corporations since 1930 for
ophthalmological, dermatological, otolaryngological
purposes, for endovenous immunoglobulin, and vaccine
preparation. Previously available vaccines containing
thimerosal were DTP, Haemophilus Influentiae, DT,
hepatitis B, Influenza, Neisseria Meningitis, Steptococcus
Pneumoniae and Rabies vaccines. In 1998 the “Centers of
Disease Control and Prevention” has recommended the
complete removal of thimerosal from vaccine,
because of a possible cerebral toxicity induced by this
preservative. Indeed, the cumulative amount of
methyl-mercury to which children were exposed in the
first 6 months of life exceeded the recommended dose of
187,5 mcg, that has been assessed as inoffensive [64].
From 2001, in developed countries, thimerosal has been
removed from pediatric vaccines. Nevertheless, some
preparations of Td, DT, influenza (mainly in multi dose
vials), meningococcal (multidose vials) vaccines
could contains minimal, not significant, trace amounts
(<1 mcg/0,5 ml). However mercury’s toxicity has never
been fully demonstrated by scientific studies, and toxic
levels were extrapolated from studies conducted on
methyl-mercury’s toxicity, which is way more toxic and
has a half-life 7 times less than mercury [65]. Current
evidence sustains the safety of the use of thimerosal as a
preservative for inactivated vaccines [66] . This
supports the administration of multidose vials of
thimerosal-preserved vaccines, especially in low- and
middle-income countries, where they are a critical part
of immunization programs [67]. Thimerosal’s
sensitization could be investigated by patch tests and it is
detectable in 10% of the general population. It is more
frequent in those countries that are more exposed to
thimerosal containing preparations, in patients
affected by atopic dermatitis or conjunctivitis and in
subjects treated with desensitization thimerosal-containing
therapies [68]. Thimerosal is responsible for delayed
hypersensitivity reactions, among which atopic dermatitis
and local skin injection reactions [69]. Only onegeneralized cellular-mediated reaction has been reported
after influenza vaccination [70]. Even in patch positive
subjects, exposure to thimerosal is considered safe [68,71]
and no contraindications are reported [72].
Phenoxyethanol – 2-phenoxyethanol (2-PE) is an
antibacterial additive associated with delayed
hypersensitivity reactions. Sensitization’s rate to 2-PE
is pretty low, local allergic reactions are rare and no
systemic reaction has been reported [73].
Antibiotics - Many vaccines contain little amounts of
antibiotics such as neomycin, aminoglycosides,
streptomycin, polymixin, tetracycline, and the fungicide
amphothericin B, to prevent bacterial and fungal
contamination. No vaccine contains beta-lactams or
sulfonamides. Until now, only a few case-reports of
vaccine adverse reactions due to antibiotics has been
reported [5]. Although, a proven anaphylaxis or
allergy to one or more antibiotics contained in
vaccines is considered an absolute contraindication
to those vaccines.
Adjuvants
Aluminium salts (aluminium hydroxide, aluminium phos-
phate, aluminium potassium sulphate) are widely used as
adjuvants in vaccines and in allergy immunoterapy, due to
their immunogenic effect. This activity, once thought to
be due to “depot” effect, is probable caused by an
increased activity of antigen presenting cells or by an
increase of cytokines and complement production [74].
DTP, hepatitis A and B, Haemophilus Influentiae B
vaccines are prepared adsorbing the antigens in either an
aluminium hydroxide or aluminium phosphate gel. As an
alternative, antigens are precipitated in a solution of alum.
Interestingly, children are anyhow exposed to aluminium
salts since they are also detectable in breast milk and in
artificial powder milk. No anaphylaxis to aluminium salts
have been reported. The most known and frequent
reaction is a palpable nodule at the injection site [75].
Sterile abscesses [76], localized or systemic dermatitis
due to aluminium salts have been reported [53].
Contaminants
Latex
Latex could be detected in vaccine’s vial or syringe. A
contamination of vaccines by latex particles could rarely
induce hypersensitivity reactions in latex-allergy children,
this risk seems to be mild. In a 160,000 case-review of
vaccine adverse events in the US, only 28 cases could have
been attributed to an IgE mediated latex-allergy [77].
Nowadays, most vaccinal preparations are latex free. If a
known latex-allergic patient requires a vaccine only
available with latex contamination, it is suggested to
remove the cap from the vial and to avoid the contact
between the cap and the needle. If a contaminating piece
Franceschini et al. Clinical and Translational Medicine  (2015) 4:3 Page 7 of 8could not be removed or avoided, normally administer
the vaccine and have the patient under a 60 minutes
supervision (Table 2) [41].
Conclusions
Children with allergy to non-active components of vaccines
are rare. When they receive a vaccine containing the con-
stituent to which they are hypersensitive, the risk of having
an allergic reaction is small. However, this risk should not
be neglected since a high number of doses are adminis-
tered. Vaccinators should be able to identify children at risk
for allergic reactions to vaccine. An allergological evaluation
may be sought in selected cases to assess how and when
vaccines may be given. In subjects at high risk, the vaccine
can be safely given with precaution, when necessary giving
administering doses, and with available materials and
support for the treatment of anaphylaxis. This may
avoid unnecessary incomplete vaccinations.
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